Clinical Trials on Stent-graft in New Zealand

Total 206 results

NYU Langone Health

Withdrawn

Comparison of Stent Suturing Versus OTSC Stentfix

Esophageal Stent Fixation

United States
NYU Langone Health

Completed

Eponychial Stent Study

Nail Bed Injury | Eponychial Stent

United States
Mayo Clinic

Enrolling by invitation

Optimal Stent Duration After Ureteroscopy

Ureteral Stent

United States, Canada
Boston Scientific Corporation

Active, not recruiting

A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) (AGENT IDE)

In-Stent Restenosis

United States
Midwest Cardiovascular Research Foundation

Completed

JetStream Atherectomy for the Treatment of In-stent Restenosis (JET-ISR)

Femoropopliteal In-stent Restenosis

United States
University of Rochester

Withdrawn

Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease

Active Chronic Graft Versus Host Disease

United States
Columbia University
Incyte Corporation

Terminated

Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease (GVHD)

Graft Vs Host Disease | Steroid Refractory GVHD

United States
NYU Langone Health

Recruiting

High-Dose Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD) Following Allogenic Hematopoietic Stem Cell Transplantation (HSCT) Study

Graft-versus-host Disease

United States
NYU Langone Health

Active, not recruiting

Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention

Graft-versus-host Disease

United States
M.D. Anderson Cancer Center

Completed

Experience of Having Chronic Graft-Versus-Host Disease

Graft-Versus-Host Disease

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Terminated

Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease

Graft Versus Host Disease

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Completed

Lactobacillus Rhamnosus GG in Reducing Incidence of Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant

Graft Versus Host Disease

United States
University of Rochester

Terminated

Positron Emission Tomography - Computed Tomography (PET-CT) Scanning in Chronic Graft Versus Host Disease (cGvHD)

Chronic Graft Versus Host Disease

United States
Yale University

Terminated

Rapamycin for Prevention of Chronic Graft-Versus-Host Disease

Graft Versus Host Disease

United States
Incyte Corporation

Completed

GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease

Graft-versus-host Disease (GVHD)

United States, Spain, Belgium, France, Italy, Korea, Republic of, Finland, United Kingdom, Germany, Israel, Switzerland, Austria, Australia, Czechia, Greece, New Zealand, Poland, Portugal, Taiwan
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease

Graft Versus Host Disease

United States, Canada, Australia, Switzerland, Puerto Rico, New Zealand
Mesoblast, Inc.

No longer available

Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (GVHD)

Graft-Versus-Host Disease

United States
Equillium
Biocon Limited

Recruiting

A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)

Graft Versus Host Disease | GVHD | aGVHD | Acute-graft-versus-host Disease | Acute GVHD

United States, Korea, Republic of, Germany, Israel, Spain, Belgium, Italy, Australia, France, Canada, Portugal, New Zealand
Northwell Health

Withdrawn

MicroRNAs as Diagnostic and Predictive Biomarkers for Acute Graft Versus Host Disease

Acute GVH Disease

United States
Alexion Pharmaceuticals

Terminated

A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease (GIGVHD)

Acute Graft-Versus-Host Disease | GIGVHD

United States, France
NYU Langone Health

Recruiting

Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD

Graft Vs Host Disease

United States
Columbia University

Completed

Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients

Implant or Graft; Rejection

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Terminated

Gluten Free Diet in Preventing Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplant

Graft Versus Host Disease | Hematopoietic Cell Transplantation Recipient

United States
Soligenix

Terminated

Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)

Chronic Gastrointestinal Graft vs Host Disease

United States
Regimmune Corporation

Completed

RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation

Graft Vs Host Disease | Graft-versus-host-disease | Acute-graft-versus-host Disease | Prevention of aGVHD

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Beclomethasone Plus Prednisone in Treating Patients With Graft-Versus-Host Disease

Graft Versus Host Disease

United States
NYU Langone Health

Completed

High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

GVHD

United States
Roswell Park Cancer Institute

Completed

Compassionate Use of Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Gastrointestinal Tract

Graft Versus Host Disease

United States
Genentech, Inc.

Terminated

A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)

Acute Graft-versus-host Disease

United States, Canada
Abbott Medical Devices

Completed

SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

Myocardial Ischemia | Coronary Artery Disease | Stent Thrombosis | Vascular Disease | Coronary Artery Stenosis | Stents | Total Coronary Occlusion | Coronary Artery Restenosis

United States
Hackensack Meridian Health

Terminated

In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus (T-REG)

Graft Versus Host Disease

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease

Graft Versus Host Disease

United States
Incyte Corporation

Approved for marketing

An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

Graft-versus-host Disease (GVHD)

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease

Chronic Graft Versus Host Disease

United States
Genentech, Inc.

Completed

Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Acute Graft-versus-host Disease

United States
Incyte Corporation

Completed

Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD

Graft-versus-host Disease (GVHD)

United States
Cynata Therapeutics Limited

Completed

A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease

Graft vs Host Disease

Australia, United Kingdom
Mallinckrodt
Parexel

Completed

Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)

Chronic Graft Versus Host Disease

United States, France, Germany, United Kingdom, Spain, Italy, Austria, Hungary
Massachusetts General Hospital
Dana-Farber Cancer Institute; Seagen Inc.

Completed

Brentuximab Vedotin for Steroid Refractory GvHD

Graft vs. Host Disease

United States
Novartis

Completed

Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients

Kidney Transplantation | Graft Rejection

United States
John Levine

Completed

Itacitinib for Low Risk GVHD

GVHD | Low Risk Acute Graft-versus-host Disease | Graft-versus-host-disease

United States
EVIVE Biotechnology
Memorial Sloan Kettering Cancer Center

Completed

Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD

Acute Graft vs Host Disease

United States
The University of Queensland
Baxter Healthcare Corporation; Health Research Council, New Zealand; Australian...

Completed

Better Evidence for Selecting Transplant Fluids (BEST-Fluids)

End Stage Kidney Disease | Kidney Transplant; Complications | Delayed Graft Function

Australia, New Zealand
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients

Graft Rejection | Kidney Failure

United States, Spain, Canada, Switzerland, Austria, Australia, New Zealand
NYU Langone Health

Withdrawn

Preventing Esophageal Stent Migration in Esophageal Strictures

Stent Migration

United States
Memorial Sloan Kettering Cancer Center

Completed

A Study to Assess Thymic Function Using PET/CT and MRI

CD34 Selected Peripheral Blood Stem Cell Graft

United States
Incyte Corporation

Completed

A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

Graft-versus-host Disease (GVHD)

United States
Plexision
Medical University of South Carolina

Unknown

Cell-based Assays for Antibody-mediated Transplant Rejection

Antibody-Mediated Graft Rejection

United States
John Levine
Biogen

Completed

Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease

Acute Graft Versus Host Disease

United States
Jazz Pharmaceuticals

Completed

An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)

Acute-graft-versus-host Disease | Graft-versus-host Disease

United States, Belgium, United Kingdom, Greece, Germany, Spain, France, Italy, Austria, Canada, Bulgaria, Croatia, Poland, Portugal

Clinical Trials on Stent-graft in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations